CAPLIPOINT

Caplin Point Laboratories share price & financials

Price
₹2,503.5
Market cap
₹19.5k Cr
Sector
Healthcare
Calls analysed
6
Latest concall · Q1 FY27 · call held 12 Aug 2026

Caplin Point Laboratories Limited Q1 FY27

EBITDA Margin 38.4% PAT ₹179 cr +19%Gross Margin 59.8% PBT ₹225.2 cr +22%

What went well

  • Overall revenue grew by 20% YoY, driven by 18% growth in the conventional market and 26% in the US market.
  • US subsidiary revenue increased threefold from INR 14.4 crores to INR 43.7 crores.
  • EBITDA margin improved from 37.7% to 38.4% due to better operating efficiency.

What to watch

  • Cash flow from operations (CFO) was INR 95 crores, lower than expected due to a strategic increase in warehouse stock by INR 76 crores and RM/PM inventory by INR 15 crores.
  • PBT profitability for the 'rest of the world' segment saw a slight decline from 37.5% in Q1 FY26 to approximately 33% this quarter, attributed to increased marketing expenses.
Read the full call →

What Caplin Point Laboratories Limited does

Caplin Point Laboratories is a Chennai-headquartered pharmaceutical company that manufactures and markets generic and branded-generic formulations, along with injectables and APIs, primarily for underserved markets in Latin America and Francophone Africa. It earns through a distribution-led, asset-light model - running in-house manufacturing facilities across Tamil Nadu, Puducherry and Andhra Pradesh while outsourcing part of production to Chinese partners - and increasingly through its own regulated-market front end, Caplin Steriles USA, which sells sterile injectables and ophthalmic products directly to US wholesalers and healthcare institutions. Its product basket spans thousands of registered products across dozens of therapeutic segments, and it has expanded from pure contract manufacturing into research-led drug development, including oncology, APIs and complex injectable dosage forms.

Segments

  • Emerging Markets (Latin America & Africa)
  • US & Other Regulated Markets
Countries with commercial presence
23
In-house manufacturing facilities
9
Dedicated R&D setups
5 (3 DSIR-approved)
Products registered globally
5,000+
Pharmaceutical formulations
650+
Therapeutic segments covered
36
Founded 1990Headquarters Chennai, Tamil Nadu, India Company website

Guidance record · Q1 FY27

what the last two calls moved 13 tracked 1 delivered 2 missed 10 open
  • Total ANDA Tally delivered said Q2 FY26 Promised: Touching around 45-46 ANDAs in the coming few weeks. Q1 FY27: No new update. Promise was achieved in the previous quarter.
  • Caplin Steriles $100M Run Rate went quiet said Q4 FY25 Promised: $100M run rate, to be achieved in 'next year or 18 months after next year'. Q1 FY27: No specific update on the $100M run rate target, despite extensive discussion on CSL's growth and capacity expansion.
  • API Facility Completion delayed said Q4 FY25 Promised: One API facility to be completed in another 2-3 months. Q1 FY27: The completion timeline for new factories, including the API plant, has been extended significantly. Management now states: 'Once we complete these factories, although it may take one or two years or two and a half years, we are sure of increasing our business manyfold.'

All 13 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 10.9%, net profit up 39.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue208 185 174 183 175 −16%189 +2%191 +10%203 +11%
EBITDA98 77 75 87 76 −22%92 +19%84 +12%94 +8%
Net profit106 75 86 86 103 −3%87 +16%110 +28%120 +40%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +24.1% 1Y

₹1.5k₹2.0k₹2.5kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 6 Nov 2025Q3 FY26 — 5 Feb 2026Q4 FY26 — 14 May 2026Q1 FY27 — 12 Aug 2026

1Y: ₹2,219.7 on 10 Sept 2025 → ₹2,754.9. High ₹2,845 (3 Sept 2026), low ₹1,504.8 (30 Mar 2026).

How the price took the results

close before → close after

Q1 FY27
−6.0%
12 Aug
Q4 FY26
+9.9%
14 May
Q3 FY26
−0.3%
5 Feb
Q2 FY26
+0.5%
6 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue fell 20.4% a year over 3 years, FY23 to FY26. Operating margin widened to 45.9%.

Year endingFY23FY24FY25FY26
Revenue₹1.5k Cr₹625 Cr₹753 Cr₹738 Cr
Operating profit₹441 Cr₹287 Cr₹331 Cr₹339 Cr
Operating margin30.1%45.9%44.0%45.9%
Interest₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Depreciation₹44 Cr₹28 Cr₹24 Cr₹25 Cr
Net profit₹376 Cr₹283 Cr₹340 Cr₹386 Cr
Net margin25.6%45.3%45.2%52.3%
Cash from operations₹157 Cr₹111 Cr₹196 Cr₹215 Cr
Free cash flow₹98 Cr₹88 Cr₹139 Cr₹170 Cr
ROCE28.0%29.0%29.0%27.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹15 Cr₹15 Cr₹15 Cr₹15 Cr₹15 Cr₹15 Cr
Reserves₹744 Cr₹915 Cr₹1.1k Cr₹1.4k Cr₹3.1k Cr₹2.0k Cr
Borrowings₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹5 Cr₹2 Cr
Other liabilities₹101 Cr₹123 Cr₹162 Cr₹131 Cr₹339 Cr₹159 Cr
Total liabilities₹861 Cr₹1.1k Cr₹1.3k Cr₹1.5k Cr₹3.5k Cr₹2.2k Cr
Fixed assets₹183 Cr₹162 Cr₹157 Cr₹166 Cr₹555 Cr₹223 Cr
Capital work in progress₹1 Cr₹3 Cr₹43 Cr₹28 Cr₹177 Cr₹9 Cr
Investments₹149 Cr₹265 Cr₹485 Cr₹584 Cr₹636 Cr₹1.0k Cr
Other assets₹528 Cr₹624 Cr₹618 Cr₹745 Cr₹2.1k Cr₹932 Cr
Total assets₹861 Cr₹1.1k Cr₹1.3k Cr₹1.5k Cr₹3.5k Cr₹2.2k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs trimmed −0.40 pp while DIIs added +0.27 pp.

Promoters
70.6%
FIIs
5.8%
DIIs
2.5%
Public
21.2%

Since Jun 2025

  • FIIs −0.40 pp
  • DIIs +0.27 pp
  • Public +0.13 pp

How it drifted, 12 quarters

Over this window the public fell from 26.1% to 21.2% — −4.9 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 70.6%, FIIs 3.1%, DIIs 0.2%, Public 26.1%.Dec '23: Promoters 70.6%, FIIs 2.8%, DIIs 0.4%, Public 26.1%.Mar '24: Promoters 70.6%, FIIs 3.3%, DIIs 1.1%, Public 24.9%.Jun '24: Promoters 70.6%, FIIs 3.4%, DIIs 1.5%, Public 24.6%.Sep '24: Promoters 70.6%, FIIs 3.7%, DIIs 1.8%, Public 23.9%.Dec '24: Promoters 70.6%, FIIs 4.9%, DIIs 2.1%, Public 22.5%.Mar '25: Promoters 70.6%, FIIs 5.7%, DIIs 2.0%, Public 21.7%.Jun '25: Promoters 70.6%, FIIs 6.2%, DIIs 2.2%, Public 21.1%.Sep '25: Promoters 70.6%, FIIs 6.5%, DIIs 2.1%, Public 20.8%.Dec '25: Promoters 70.6%, FIIs 6.6%, DIIs 2.0%, Public 20.8%.Mar '26: Promoters 70.6%, FIIs 6.2%, DIIs 2.1%, Public 21.1%.Jun '26: Promoters 70.6%, FIIs 5.8%, DIIs 2.5%, Public 21.2%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Caplin Point Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
P Vijayalakshmi 24.71%unchanged
Paarthipan C C 18.64%unchanged
Ashok Gorkey Partheeban 11.91%unchanged
Partheeban Vivek Siddarth 11.85%unchanged
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 2.87%−0.17 pp
May India Property Private Limited 2.79%unchanged
UTI Multi Cap Fund Mutual fund1.81%unchanged
Pinebridge Global Funds - Pinebridge India Equity Fund FPI fund1.05%unchanged
First Dimension Holdings Private Limited 0.49%unchanged
Kiraviz Properties And Consultancy Llp 0.20%unchanged
Kotteswari B 0.00%unchanged
Soundari B 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in CAPLIPOINT

Filings to Aug 2026

0 new, 4 added, 1 trimmed, 0 sold out — net +0.01 L shares (+1.1%).

Held by funds
₹13 Cr
5 schemes
Biggest holder
Nippon India Nifty Smallcap 250 Index Fund
₹8 Cr · 0.2% of that fund
SchemeHoldingLast month
Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund₹8 Cr+0.00 L
SBI Nifty Smallcap 250 Index Fund SBI Mutual Fund₹4 Cr+0.00 L
Nippon India Nifty 500 Equal Weight Index Fund Nippon India Mutual Fund₹1 Cr+0.00 L
SBI Nifty 500 Index Fund SBI Mutual Fund₹0 Cr−0.00 L
SBI Nifty Small Cap 250 ETF SBI Mutual Fund₹0 Cr+0.00 L

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

4 added, 1 trimmed — net +570 shares (+1.1%)

Funds are sitting on
+52%
vs est. average cost
Held by funds
₹13 Cr
5 schemes · ≈ 0.07% of the company
Biggest holder
Nippon India Nifty Smallcap 250 Index Fund
₹8 Cr · 0.2% of that fund

Shares held by these funds +272%

Dec '22 52,168 shares Jul '26

What the price assumes

Growth trap

To justify its price of ₹2755, this stock must grow earnings at 36% every year for 7 years. Our analysis caps realistic growth at ~1%. At that growth it is worth ₹453 — downside of 84%.

Growth the price implies
35.7% a year
for 7 years, fading to 4%
It has actually compounded at
0.9% a year
net profit, FY23–FY26 · EPS 0.7%
The gap
0.3 pp
-84% downside if it only repeats history
Price today ₹2,754.9 Value at the reference growth ₹453.07

Change the assumptions yourself →

All earnings calls (6)

Read the Q1 FY27 call →

Learn to analyse Caplin Point Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.